Cipla Shifts Focus To India To Drive Growth
Country's fourth-largest drug maker Cipla Ltd. is bullish on growth and is looking for a billion dollar consolidated revenue for the domestic market in FY19, a senior company official said.
The company reported revenue of Rs 15,219 crore, growing 6 percent, with income from the India operations seeing a 6.3 percent jump at Rs 5,687 crore in FY18.
“In terms of the domestic business we are on a strong footing as growth was in healthy double digits,” Cipla global CFO Kedar Upadhye said at an earnings conference here.
“We are quite confident and we are set for a billion dollar consolidated revenue in the domestic market in FY19,” Upadhye added.
The drugmaker expects the in-licensing deals with innovator companies, focus on certain therapeutic segments and sales force productivity optimisation measures to aid growth in India.
This financial year, our focus remained on strengthening our portfolio and deepening our presence in priority markets. We are happy that our efforts on cost and efficiency improvement helped us deliver the full year margin ahead of our guidance range.Umang Vohra, Managing Director and Global CEO, Cipla
The focus for next year will be to continue on the growth trajectory in key markets, he added.
Commenting on inorganic growth plans, Vohra said, “We have taken an enabling resolution, does not mean that we will be doing deals worth Rs 4,000 crore. As and when they become available, we will be hopeful (of acquisition), but we will not buy unless we see a synergy value in the transaction.”
Last year the company had taken an enabling resolution to raise funds of about Rs 2,000 crore of debt and Rs 2,000 crore of equity. The company is also looking at consolidating its position in South Africa, U.S., Europe and emerging markets.
“We will ramp up our U.S. business, which is poised for good growth during this year with our key differentiated launches,” Vohra said.
The company is also looking at significant investments in R&D to build a strong pipeline, with over 20 targeted filings in FY19. This year will also see higher investments towards clinical trials for key respiratory assets and focus on building specialty assets, Vohra added.
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.
-
You May Inherit The Business. You Must Earn Its Credibility.
Succession tests the founder's ability to share authority as much as it tests the next generation's readiness to assume it.
-
Signing Deals Is One Thing; Making Them Work Is Another | The Week In Whys
Sometimes, things don't turn out as planned. Indian companies have lost some bids to rivals, some projects won't produce until 2030.
-
FOMC Wall, PERM Suspension, Hospital Stocks | Talking Points This Week
A PERM suspension would directly affect green-card sponsorship rather than H-1B visas, so the near-term earnings impact could remain relatively limited. The key question is whether this marks a new phase in US scrutiny of Indian IT.
